— Know what they know.
Not Investment Advice

NBY AMEX

NovaBay Pharmaceuticals, Inc.
1W: +25.3% 1M: +27.0% 3M: -93.6% YTD: -93.6% 1Y: -0.5% 3Y: -99.0% 5Y: -100.0%
$1.47
Last traded 2026-04-06 — delisted
AMEX · Healthcare · Biotechnology · $39.1M mcap · 26M float · 2.09% daily turnover · Short 33% of daily vol
Smart Money Score
Watch 0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$39.1M
52W Range1.11-99.75
Volume86,826
Avg Volume552,072
Beta0.16
Dividend$4.00
Analyst Ratings
2 Buy 3 Hold 0 Sell
Consensus Hold
Company Info
CEOMichael Kazley
Employees13
SectorHealthcare
IndustryBiotechnology
IPO Date2007-10-26
2000 Powell Street
EmeryVille, CA 94608
US
510 899 8800
About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.

Recent Insider Trades

NameTypeSharesPriceDate
Lazar David E. A-Award 6,388,000 — 2025-10-21
Lazar David E. M-Exempt 39,925 — 2025-10-21
Framework Ventures I C-Conversion 56,806,080 — 2025-10-21
R01 Fund LP C-Conversion 56,806,080 — 2025-10-21
Kazley Michael John C-Conversion 56,806,080 — 2025-10-21

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms